Reports Q3 revenue $516,000, consensus $270k. “The third quarter was transformative for IGM, punctuated by the announcement of our strategic pivot to focus exclusively on autoimmunity,” said Mary Beth Harler, M.D., Chief Executive Officer of IGM Biosciences (IGMS). “Our near-term focus for imvotamab remains generating robust initial data sets in rheumatoid arthritis, systemic lupus erythematosus and myositis. Based on enrollment timing, we expect to have sufficient information by the middle of 2025 to present initial imvotamab data at an appropriate venue as well as determine next steps to advance imvotamab in autoimmune indications.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- IGM Biosciences price target raised to $20 from $17 at RBC Capital
- Biotech Alert: Searches spiking for these stocks today
- IGM Biosciences Shifts Focus to Autoimmunity, Appoints New CEO
- Morning Movers: McCormick and Paychex rise following quarterly reports
- IGM Biosciences price target lowered to $22 from $25 at Wedbush